Member Info for moonparty

Yes, definitely an issue for all personalised vaccines Desouzaa.

My specific point is that it introduces a bias in the results which is a major problem in comparing with standard of care and non-personalised vaccines, and that needs to be highlighted.

So I have done a bit of digging into Evaxion and the EVX-01 trial, and I can see a major flaw in using this as a comparison for either standard of care or other trials such as Scancells.

In a nutshell, it's the 12 week wait for treatment, as that's the time it takes to manufacture the vaccine. This is key in understanding why the trial numbers reduced from an initial 75 to an eventual 16:

Some patients were excluded before receiving the treatment because of rapid disease progression before the vaccine production was completed, failure to meet inclusion criteria on reevaluation, or technical issues during DNA sequencing. This led to fewer patients being enrolled than originally planned.

So, imagine a starting line of 75 patients with very poor prognosis, then wait 12 weeks and exclude those that have passed away or progressed to an extent that they are too poorly to meet the trial entry criteria. What you are left with is a sub-set of the most well patients - i.e. those most likely to have a superior outcome on the checkpoint inhibitor alone.

Surely this makes the data incomparable to other trials that start administration of the treatment on day 1?

Happy to be corrected here - I have studied the trial design and entry criteria here (and compared to Scancells - they entry and exclusion criteria are very similar), but can't see that this accounted for in any way shape or form:

https://clinicaltrials.gov/study/NCT05309421

Cleanerworld, you need to get a letter of admission from your broker - should be a standard request. I use interactive investor, and you can request the letter from their website.

Pretty sure all or most of the 9.84 and 9.86 trades were sells. I was being offered 9.86 for 300k when I checked.

The higher the chance of a take out?

Current mkt cap about £5M, would the technology be worth a cheeky bid of £10M to a competitor?

I'm getting tempted - thoughts anyone? Is this a possibility or am I overlooking something?

Are interesting - lots of very small matching trades at the quoted bid and offer? And some of them are zero volume!! never seen that before?

Any conspiracy theories as to what this means?

The calm before the storm?

To finish last sentence:

This is a change in language - at the recent Q & A, they seemed confident on partnering but fund-raising (i.e. placing) was also mentioned.

Ivy, I don't think there is new information in the annual report.

However the report is strongly signalling partnering rather than fund-raising. This is a change in language - at he recent

"we are in active discussions with potential partners to find the right development path forward, with timely development and shareholder value in mind. "

Think it is showing Kash, 200K for 9.75p at 10:22 ?

Seems to be a stalemate - plenty of volume going through and plenty available on bid and offer (you can buy/sell 300,000 instantly).

Indicates seller(s) are still offloading but buyer(s) are lapping it all up.

I expect we'll have a holdings announcement in due course.

Sorry Berm, my post not meant as a criticism of yours, just making the point that they are rolling out the big guns and there will be a reason for that.

It's getting quite exciting now, so much is going to happen before Christmas, maybe we will all get the gift we deserve after all these years 🎁😊

A lot of senior staff attending for just an eposter, there will be planned meetings as well.

With respect RR, I don't think you can speak for other shareholders. And what it is 'worth' is not necessarily related to the current sp or the broker target - this is AIM, which is not an efficient market. It's why research is so important if you're going to put your hard-earned cash into AIM stocks.

I for one can see £8 is quite possible within a relatively short time frame.

Well, yes, I can see a pathway to a much higher share price, wouldn't be here otherwise. The last year or 2 has seen massive change in the running and attitude of Scancell, and they are incredibly well positioned and staffed to reap the financial rewards of the ground breaking science.

If the data for scib / modi is as expected, I can see a clamour for a piece of the action from partners and/or funds and a very fast re-rate within the next 12 months, possibly into the multiple pounds, more likely to around £1. With some more potential from Glymabs / Avidimab ?

Going forward from this, a supportive partner for phase 3 trial(s) and an end to funding worries should see the SP on a vaguely upward path.

However, IMO, to get full value (multiple pounds per share), Scancell has to move it's listing to the Nasdaq, and I am hoping this will be part of any partner deal for phase 3. AIM is not doing Scancell any favours.

Would also like to stress ratcliffes point - research, research, research. Understand the science and make up your own mind. Melanoma is the graveyard of startups, so understand why Scancell are succeeding where others have failed - it will help you sleep at night!

They've already found it old, just jumping through the hoops now.

A UT trade of size 666 to set the closing price!

Looks likely - if you can bear it, trawl through the post on the dark side for chilltime's excellent analysis.

And seems they have sold all their shares or are very close. Should indicate a rising price going forward.

Not a current holder (haven't been for years) but the board change is good news for the future of Parsortix IMO.

Any new board will hopefully be well connected and able to ramp up the sales.

Maybe not so good for shareholders - a serious chance this will be taken private by the controlling shareholders - might be good for long-term holders, but not for those invested via SIPPs and ISAs as they will be forced to sell.

Also a fighting chance the controlling shareholders will let it go bust and salvage the business from the liquidators at a knock down price (and eliminate other shareholders).

Happy path is that the new board keep the listing, get a decent funding away and ramp up sales - if this scenario unfolds, buying today will be a steal.

Too risky for me, but watching with interest.